Skip to content

Prevalence of FGIDs and Probiotics Study

Center of Excellence in Thai Pediatric Gastroenterology, Hepatology and Immunology

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06309199
Acronym
PROOF
Enrollment
512
Registered
2024-03-13
Start date
2024-03-14
Completion date
2026-02-28
Last updated
2025-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional Gastrointestinal Disorders, Infant Conditions

Keywords

functional gastrointestinal disorder, colic, regurgitation, constipation, infant, prevalence

Brief summary

This is a study to evaluate the prevalence of FGIDs in infants using the Thai version of Rome IV diagnostic questionnaire for functional gastrointestinal disorders in infants and evaluate the efficacy of Limosilactobacillus reuteri DSM 17938 to prevent FGIDs in infants.

Detailed description

This is a randomized controlled trial study about the the efficacy of Lactobacillus reuteri DSM 1987 to prevent FGIDs in healthy infants and the effect to gut microbiota diversity. The incidence of FGIDs in Thai infant using Thai version of ROME IV questionnaire (authorized by Rome Foundation) for infant and toddler and the associated factors of FGIDs also evaluate. Population: target and control populations are the healthy infants born at King Chulalongkorn Memorial Hospital, Bangkok, Thailand, and can come to follow up at the hospital at 1, 2, 4, and 12 months of age Inclusion criteria 1. Healthy and term (GA 37-41 weeks) infants 2. Appropriate weight for age 3. APGAR score more than 8 at 10 minutes of life 4. Normal physical examination 5. Mothers have no previous probiotics use Methodology * Participants were double-blinded randomized using computer generation in block of four * Target population were received Limosilactobacillus reuteri DSM 17938 5 drops (0.185 mL) per day for 60 days * Control population were received mixture of sunflower oil and MCT oil 5 drop (0.185 mL) per day for 60 days * There were 5 visits at birth, 1, 2, 4, 12 months of life: the demographic data/Rome IV questionnaire for FGIDs in infant and associated factors with FGIDs record, physical examination and stool collection The study will be analyzed (open the randomized group) after all participants complete the 4-month follow-up period * Research assistance will telephone to them to take the Rome IV questionnaire for FGIDs at 3, 6, 9 months of life Biological specimen collection Stool will be collected by rectal stimulation in each visit. The amount of \>5 gm stool will be preserved in DNA and kept at -80 °C. All stool specimen will be processed the DNA extraction (DNA \> 40 microlitre with concentration \>50 ng/L). The DNA extraction for further amplification 16S rRNA using Illumina. The rest of the specimen will be kept up to 10 years for further evaluation.

Interventions

DIETARY_SUPPLEMENTBiogaia

Biogaia is a probiotics product that contain Limosilactobacillus reuteri DSM 17938, sunflower oil and MCT oil

OTHERPlacebo

Limosilactobacillus reuteri DSM 17938, sunflower oil and MCT oil

Sponsors

Chulalongkorn University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Masking description

These 2 groups was assigned using computer generate with block of 4 and ratio 1:1. The intervention and placebo were prepare in the same container with the same color, odor and blinded to investigators, participants and guardians.

Intervention model description

Intervention group received probiotics Control group received sunflower and MCT oil

Eligibility

Sex/Gender
ALL
Age
3 Days to 1 Years
Healthy volunteers
Yes

Inclusion criteria

1. Healthy and term (GA 37-41 weeks) infants 2. Appropriate weight for age 3. APGAR score more than 8 at 10 minutes of life 4. Normal physical examination 5. Mothers have no previous probiotics use

Exclusion criteria

1. not willing to anticipate in the study 2. cannot come to follow-up until 1 year of age

Design outcomes

Primary

MeasureTime frameDescription
The prevalence of functional gastrointestinal disorders in the treatment groupat birth, 1 month, 2 months, 4 monthsFunctional gastrointestinal disorders (colic, regurgitation, constipation, dyschazia and rumination) were assessed using the Thai version of Rome IV diagnostic questionnaire for neonates and toddlers

Secondary

MeasureTime frameDescription
The prevalence of functional gastrointestinal disorders in the placebo groupat birth, 1 month, 2 months, 4 months and 1 year (5-time points)Functional gastrointestinal disorders (include colic, regurgitation, constipation, dyschazia and rumination) were assessed using the Thai version of Rome IV diagnostic questionnaire for neonates and toddlers
The prevalence of functional gastrointestinal disorders in the treatment groupat 1 year of ageFunctional gastrointestinal disorders (colic, regurgitation, constipation, dyschazia and rumination) were assessed using the Thai version of Rome IV diagnostic questionnaire for neonates and toddlers

Other

MeasureTime frameDescription
The sleep quality assessed by Brief Infant Sleep Revise Questionnaire of BISQRat birth, 1 month, 2 months, 4 months and 1 year (5-time points)The questionnaire has 33 items in 3 main categories (Infant sleep, parent perception and parent behavior). Scores on each subscale and the total score are scaled from 0 to 100. Higher score denote better sleep quality.
Stool metabolomic substances (i.e microbial conjugation of secondary bile acid, aminoacid) and the stool metabolites alterationat birth, 1 month, 2 months and 4 monthsFecal metabolomic substances (i.e microbial conjugation of secondary bile acid, aminoacid) were assesse using liquid chromatography-mass spectrometry (LC-MS), gas chromatography-mass spectrometry (GC-MS) and capillary electrophoresis-mass spectrometry (CE-MS)
Fluid intake associated with functional gastrointestinal disorders in infantsat birth, 1 month, 2 months and 4 months and 1 year (5-time points)type of milk (breastfeeding or formula or mixed) and amount (mL per kg body weight)
Stress associated with functional gastrointestinal disorders in infantsat birth and 1 yearstress in family (i.e divorce, family dept present as yes or no)
Nutrition associated with functional gastrointestinal disorders in infantsat 1 yearAmount of food composition (carbohydrate, protein, lipid - present as gm per kg body weight)
Economic status associated with functional gastrointestinal disorders in infantsat birth and 1 yearEconomics status (income in baht)
Education of caregiver associated with functional gastrointestinal disorders in infantsat birth and 1 yearEducation (low, high)
Serious adverse effect during follow-up until end point1 month, 2 months, 4 months, 6 months, 9 months, 1 yearsadmission, cause of admission, treatment details (intravenous fluid, medication, oxygen supplementation)
Antibiotics associated with functional gastrointestinal disorders in infantsat birth, 1 month, 2 months and 4 months and 1 year (5-time points)antibiotics use (yes or no)
Gut microbial profiles associated with functional gastrointestinal disorder in infantsat birth, 1 month, 2 months, and 4 monthsComparative metagenomic analysis of gut microbial profiles (diversity, relative abundance, species alteration) in fecal samples among different groups of infants
skin problems (seborrheic dermatitis, atopic dermatitis, nonspecific dermatitis)1 month, 2 months, 4 months, 1 yearpatient oriented- Scoring atopic dermatitis (it is an application in phone to add the information of skin lesion by doctor or parent examination), examination and record the characteristics and location of skin lesion by doctors

Countries

Thailand

Contacts

Primary ContactPalittiya Sintusek, PhD
palittiya.s@chula.ac.th+66818288082
Backup ContactSittichoke Prachuapthunyachart, MD
sittichoke.p@chula.ac.th+66829740649

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026